We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Dan Stinchcomb is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 1985 — 1986 |
Stinchcomb, Dan Thomas |
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Molecular Genetics of Embryogenesis in C. Elegans
Since the early twentieth century, embryologists have known that much of early development is controlled by information in the cytoplasm of the egg. Maternal effect genes encode that information; their function is required during oogenesis for embryogenesis to occur. One means of studying the nature and function of maternal information is to isolate maternal effect genes. The DNA sequences thus isolated can be used as probes to study the molecular basis of interactions between the egg cytoplasm and the zygotic nucleus during embryogenesis. Caenorhabditis elegans, due to its defined cell lineage, physiology, and genetics, has been widely used for studies of early development. Several maternal effect lethal (mel) genes have been identified and characterized. These genes will be isolated by DNA transformation. In preliminary studies, the first important step in DNA transformation of C. elegans has been achieved: the introduction and propagation of foreign DNA. The next step is to demonstrate expression of the exogenously added sequences. Concomitantly, DNA will be isolated that corresponds to defined genetic regions surrounding and including mel genes. This DNA will be injected into mel mutants; complementation of the mutant defect will define DNA that encodes the gene. Once isolated, mel gene sequences can be used to identify and characterize RNA and protein products. The synthesis and metabolism of information encoded by mel genes will provide insights into how genes establish cytoplasmic information and then how the cytoplasm affects gene activity. This recursive interrelationship between cytoplasm and nucleus is a central issue in cellular behavior, development and differentiation. Thus, understanding these interactions has implications for the treatment of cellular and developmental defects and neoplasia.
|
0.958 |
| 2008 |
Stinchcomb, Dan Thomas |
U54Activity Code Description:
To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
Animal Models and Preclinical Development of a Chimeric Chikungunya Vaccine @ Colorado State University-Fort Collins
Africa; Alpha Virus; Alphavirus; Americas; Animal Model; Animal Models and Related Studies; Arboviruses, Group A; Arthralgia; Asia; Attenuated; Biological; Breakbone Fever Virus; Categories; Chikungunya virus; Chronic; Clinical Evaluation; Clinical Testing; Complementary DNA; Country; Culicidae; DNA, Complementary; Dengue Virus; Development; Diagnosis, clinical; Disease; Disorder; Drug Formulations; Formulation; Formulations, Drug; Genes; Genetic; Goals; Human; Human, General; Joint Pain; Licensing; Mammals, Mice; Man (Taxonomy); Man, Modern; Medical; Mice; Modeling; Mosquitoes; Murine; Mus; NIAID; National Institute of Allergy and Infectious Disease; Persons; Preparation; Public Health; Safety; Spinal Column; Spine; Structural Protein; Testing; Texas; Universities; Vaccines; Vero Cells; Vertebral column; Viral Diseases; Viral Vaccines; Virus Diseases; backbone; cDNA; chikungunya; clinical Diagnosis; clinical test; disease/disorder; immunogenic; model organism; non-human primate; nonhuman primate; pathogen; pre-clinical; preclinical; prevent; preventing; public health medicine (field); research clinical testing; viral infection; virus infection
|
0.914 |